Abstract
Knowledge about the cytochrome P450 (CYP) inhibition potential of new drug candidates is important for drug development because of its risk of interactions. For novel psychoactive substances (NPS), corresponding data are not available. For developing a general drug inhibition cocktail assay, a liquid-chromatography high-resolution tandem mass spectrometry multi-analyte approach was developed and validated for quantifying low concentrations of O-diethyl phenacetin for CYP 1A2, 7-hydroxy coumarin for CYP 2A6, 4-hydroxy bupropion for CYP 2B6, N-diethyl amodiaquine for CYP 2C8, 4-hydroxy diclofenac for CYP 2C9, 5-hydroxy omeprazole for CYP 2C19, O-dimethyl dextromethorphan for CYP 2D6, 6-hydroxy chlorzoxazone for CYP 2E1, and 6-beta-hydroxy testosterone for CYP 3A in the incubation mixture in the presence of substrates and inhibitors. The tested matrix effects ranged from 63 to 141 % and the recoveries from 95 to 110 %. Time-saving one-point calibration allowed sufficient quantification, although some of the validation results for 7-hydroxy coumarin, 4-hydroxy bupropion, 4-hydroxy diclofenac, and 6-beta-hydroxy testosterone were outside the acceptance criteria (AC) but without influence of the IC50 calculation. Validation showed also that the approach was sensitive and selective using mass spectral multiplexing. In conclusion, the presented assay was suitable for the quantification of the model substrate metabolites and could be used for the development of a CYP inhibition assay for testing most CYPs and a wide range of drugs of abuse.
Similar content being viewed by others
References
Ortiz-de-Montellano PR (2005) Cytochrome P450—structure, mechanism, and biochemistry. Kluwer/Plenum, New York
Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831
Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23–29
Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG (2005) High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–2658
Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O (2005) Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123–132
Lee KS, Kim SK (2013) Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. J Appl Toxicol 33:100–108
Qin CZ, Ren X, Tan ZR, Chen Y, Yin JY, Yu J, Qu J, Zhou HH, Liu ZQ (2014) A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 28:197–203
Qiao X, Ji S, Yu SW, Lin XH, Jin HW, Duan YK, Zhang LR, Guo DA, Ye M (2014) Identification of key licorice constituents which interact with cytochrome P450: evaluation by LC/MS/MS cocktail assay and metabolic profiling. AAPS J 16:101–113
Ewald AH, Maurer HH (2008) 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol Lett 183:52–57
Wu D, Otton SV, Inaba T, Kalow W, Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605–1612
Remane D, Meyer MR, Wissenbach DK, Maurer HH (2010) Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. Rapid Commun Mass Spectrom 24:3103–3108
Mueller DM, Duretz B, Espourteille FA, Rentsch KM (2011) Development of a fully automated toxicological LC-MS(n) screening system in urine using online extraction with turbulent flow chromatography. Anal Bioanal Chem 400:89–100
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2006) Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling [Draft] http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf
Wille SM, Peters FT, Di-Fazio V, Samyn N (2011) Practical aspects concerning validation and quality control for forensic and clinical bioanalytical quantitative methods [review]. Accred Qual Assur 16:279–292
Peters FT, Paul LD, Musshoff F, Aebi B, Auwaerter V, Kraemer T, Skopp G (2009) Guidelines for quality assurance in forensic-toxicological analyses. Toxichem Krimtech 76:185–208, http://www.gtfch.org/cms/index.php/guidelines
European Medicines Agency (2011) Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
U.S. Department of Health and Human Services FaDA (2013) Guidance for industry, bioanalytical method validation, draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf
Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019–3030
Meyer GMJ, Meyer MR, Wink CSD, Zapp J, Maurer HH (2013) Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochem Pharmacol 86:1497–1506
Remane D, Meyer MR, Peters FT, Wissenbach DK, Maurer HH (2010) Fast and simple procedure for liquid-liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma. Anal Bioanal Chem 397:2303–2314
Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 24:1962–1973
Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A (2000) Bioanalytical method validation—a revisit with a decade of progress. Pharm Res 17:1551–1557
Acknowledgements
The authors like to thank their colleagues Andreas G. Helfer, Golo M.J. Meyer, Julian A. Michely, Andrea E. Steuer, Armin A. Weber, Jessica Welter, and Carina S.D. Wink for their support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dinger, J., Meyer, M.R. & Maurer, H.H. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail. Anal Bioanal Chem 406, 4453–4464 (2014). https://doi.org/10.1007/s00216-014-7849-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-014-7849-x